Published online before print March 5, 2007, doi: 10.1161/CIRCULATIONAHA.106.661405
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1371-1375.)
© 2007 American Heart Association, Inc.
Heart Failure |
Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk
From the Karolinska Institutet, Department of Medicine, Unit of Cardiology, Karolinska University Hospital, Stockholm, Sweden (C.H.); Population Health Research Institute, Hamilton General Hospital, McMaster Clinic, Hamilton, Ontario, Canada (C.H., H.C.G., S.Y., F.Z., K.T.); Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany (L.H.); The George Institute, Royal Prince Alfred Hospital, Sydney, Australia (C.A.); and John Radcliffe Hospital, Oxford, UK (P.S.).
Correspondence to Claes Held, Karolinska Institutet, Department of Medicine, Unit of Cardiology, Karolinska University Hospital, 17176 Stockholm, Sweden.
Received August 30, 2006; accepted December 11, 2006.
Background— Patients with diabetes mellitus (DM) are at high risk of developing congestive heart failure (CHF). However, the relationships between glucose levels and CHF in people with or without a history of DM have not been well characterized.
Methods and Results— We evaluated the associations between fasting plasma glucose and risk of hospitalization for CHF during follow-up in patients at high cardiovascular risk and without CHF enrolled in a large-scale clinical trials program. Baseline fasting plasma glucose levels were assessed in 31 546 high-risk subjects with 
1 coronary, peripheral, or cerebrovascular disease or DM with end-organ damage who are participating in 2 ongoing parallel trials evaluating the effects of telmisartan, ramipril, or their combination (Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]; n=25 620) and the effects of telmisartan against placebo in angiotensin-converting enzyme–intolerant patients (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease [TRANSCEND]; n=5926). Interim analyses blinded for randomized treatment were performed to compare baseline fasting plasma glucose with the adjusted CHF event rate at a mean follow-up of 886 days. Multivariable Cox regression models were performed, and associations were reported as hazard ratios and 95% confidence intervals. Among all subjects (mean age, 67 years; 69% men), of whom 11 708 (37%) had known DM and 1006 (3.2%) had newly diagnosed DM at baseline, 668 patients were hospitalized for CHF during follow-up. After adjustment for age and sex, a 1-mmol/L-higher fasting plasma glucose was associated with a 1.10-fold-increased risk of CHF hospitalization (95% confidence interval, 1.08 to 1.12; P<0.0001). The association persisted after adjustment for age, sex, smoking, previous myocardial infarction, hypertension, waist-to-hip ratio, creatinine, DM, and use of aspirin, ß-blockers, or statins (hazard ratio, 1.05; 95% confidence interval, 1.02 to 1.08; P<0.001).
Conclusions— Fasting plasma glucose is an independent predictor of hospitalization for CHF in high-risk subjects. These data provide theoretical support for potential direct beneficial effects of glucose lowering in reducing the risk of CHF and suggests the need for specific studies targeted at this issue.
Key Words: cardiovascular diseases • clinical trials • glucose • heart failure • risk factors
This article has been cited by other articles:
 |
|
 |
|
  D. E. Hofsten, B. B. Logstrup, J. E. Moller, P. A. Pellikka, and K. Egstrup Abnormal glucose metabolism in acute myocardial infarction influence on left ventricular function and prognosis. J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 592 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Ndisang, N. lane, and A. Jadhav The Heme Oxygenase System Abates Hyperglycemia in Zucker Diabetic Fatty Rats by Potentiating Insulin-Sensitizing Pathways Endocrinology, May 1, 2009; 150(5): 2098 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Preiss, S. Zetterstrand, J. J.V. McMurray, J. Ostergren, E. L. Michelson, C. B. Granger, S. Yusuf, K. Swedberg, M. A. Pfeffer, H. C. Gerstein, et al. Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program Diabetes Care, May 1, 2009; 32(5): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Ndisang, N. Lane, and A. Jadhav Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1029 - E1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. O. Arnold and R. E. Gilbert Novel risk factors for heart failure when the whole may be greater than the sum of its parts. J. Am. Coll. Cardiol., March 3, 2009; 53(9): 763 - 764. [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Gerstein Dysglycemia and Cardiovascular Risk in the General Population Circulation, February 17, 2009; 119(6): 773 - 775. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Noh, Y. Hu, T.-S. Park, T. DiCioccio, A. J. Nichols, K. Okajima, S. Homma, and I. J. Goldberg Regulation of Plasma Fructose and Mortality in Mice by the Aldose Reductase Inhibitor Lidorestat J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 496 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Butler, A. Kalogeropoulos, V. Georgiopoulou, R. Belue, N. Rodondi, M. Garcia, D. C. Bauer, S. Satterfield, A. L. Smith, V. Vaccarino, et al. Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score Circ Heart Fail, July 1, 2008; 1(2): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, D. T. Eurich, S. R. Majumdar, and J. A. Johnson The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy Eur J Heart Fail, July 1, 2008; 10(7): 703 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kalathil, K. Mussarat, and G. I Varughese The cardiovascular morbidity associated with hyperglycaemia J R Soc Med, March 1, 2008; 101(3): 104 - 104. [Full Text] [PDF]
|
|
|
|
|
|
L. van Heerebeek, N. Hamdani, M. L. Handoko, I. Falcao-Pires, R. J. Musters, K. Kupreishvili, A. J.J. Ijsselmuiden, C. G. Schalkwijk, J. G.F. Bronzwaer, M. Diamant, et al. Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension Circulation, January 1, 2008; 117(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Varughese, A. A. Tahrani, and J. H.B. Scarpello Letter Regarding Article, "Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk" Circulation, September 4, 2007; 116(10): e339 - e339. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Verdecchia, F. Angeli, and G. Reboldi New-Onset Diabetes, Antihypertensive Treatment, and Outcome Hypertension, September 1, 2007; 50(3): 459 - 460. [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Elevated Glucose Levels and Risk for Incident Heart Failure Journal Watch Cardiology, April 4, 2007; 2007(404): 4 - 4. [Full Text]
|
|
|
|
|
|
M. C. Petrie and J. J.V. McMurray Dysglycemia and Heart Failure Hospitalization: What Is the Link? Circulation, March 20, 2007; 115(11): 1334 - 1335. [Full Text] [PDF]
|
|